KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Payables (2017 - 2025)

Aquestive Therapeutics has reported Payables over the past 9 years, most recently at $29.9 million for Q4 2025.

  • Quarterly results put Payables at $29.9 million for Q4 2025, up 190.29% from a year ago — trailing twelve months through Dec 2025 was $29.9 million (up 190.29% YoY), and the annual figure for FY2025 was $29.9 million, up 190.29%.
  • Payables for Q4 2025 was $29.9 million at Aquestive Therapeutics, up from $10.9 million in the prior quarter.
  • Over the last five years, Payables for AQST hit a ceiling of $29.9 million in Q4 2025 and a floor of $5.7 million in Q2 2024.
  • Median Payables over the past 5 years was $10.0 million (2022), compared with a mean of $10.4 million.
  • Biggest five-year swings in Payables: tumbled 59.21% in 2021 and later surged 190.29% in 2025.
  • Aquestive Therapeutics' Payables stood at $8.3 million in 2021, then grew by 19.63% to $9.9 million in 2022, then fell by 10.26% to $8.9 million in 2023, then grew by 15.25% to $10.3 million in 2024, then surged by 190.29% to $29.9 million in 2025.
  • The last three reported values for Payables were $29.9 million (Q4 2025), $10.9 million (Q3 2025), and $12.0 million (Q2 2025) per Business Quant data.